The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elrefaei, M.
Right arrow Articles by Cao, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elrefaei, M.
Right arrow Articles by Cao, H.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*AIDS Medicines
The Journal of Immunology, 2004, 173: 2184-2189.
Copyright © 2004 by The American Association of Immunologists

Central Memory CD4+ T Cell Responses in Chronic HIV Infection Are Not Restored by Antiretroviral Therapy1

Mohamed Elrefaei2,*, Michael D. McElroy*, Christopher P. Preas*, Rebecca Hoh{dagger}, Steven Deeks{dagger}, Jeffrey Martin{ddagger} and Huyen Cao*

* California Department of Health Services, Richmond, CA 94804; and Departments of {dagger} Medicine and {ddagger} Epidemiology and Biostatistics, University of California, San Francisco, CA 94110


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
A strong CD4+ T cell response has been correlated with better control of HIV infection. However, the effect of HIV on the maintenance of Ag-specific memory CD4+ T cells is not fully understood. We characterized the function and phenotype of memory CD4+ T cells generated by mumps and influenza A or B viruses in HIV-infected individuals receiving highly active antiretroviral therapy (n = 21), HIV-infected long-term nonprogressors (n = 10), and HIV-seronegative volunteers (n = 10). We observed significantly decreased proliferation of the Ag-specific central memory CD4+ T cell population (CD28+/CCR7+/CD45RA–) in the antiretroviral treated HIV-infected individuals compared with the seronegative controls. Restored CD4+ T cell count and decreased HIV viral load while on highly active antiretroviral therapy did not result in increased proliferation, whereas nadir CD4+ T cell count predicted the presence of Ag-specific proliferation. Our results indicate that HIV infection leads to impaired maintenance of virus-induced or vaccine-generated central memory CD4+ T cells that is not restored by HAART.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Protection following viral clearance or successful immunization requires the generation and maintenance of long-lived Ag-specific CD4+ Th cells, defined as central memory CD4+ T cells. Memory T cells have distinct phenotypes (reviewed in Ref.1). Central memory CD4+ T cells express CCR7, a homing molecule to the lymph nodes, and CD28, a costimulatory molecule that provides signals for specific CD4+ T cell activation. Central memory CD4+ T cells produce IL-2, undergo rapid expansion in response to Ag restimulation (2, 3), and are critical for the development of CD8+ T cell memory (4, 5, 6).

HIV infection results in a progressive decline in CD4+ T cell number and function, resulting in an increased risk of opportunistic infections (7, 8, 9, 10). The introduction of highly active antiretroviral therapy (HAART)3 has significantly reduced HIV-related morbidity and mortality (11, 12, 13, 14). These clinical benefits have been attributed to decreased HIV replication and increased CD4+ T cell number (reviewed in Ref.15). The full effect of HAART on T cell immunity is still debated. HAART initiation has been associated with the detection of proliferative and Ab responses following immunization with influenza vaccine (16), tetanus toxoid, and inactivated hepatitis A vaccine (17), although these responses are often incomplete (18, 19, 20, 21). We report in this work the consequence of chronic HIV infection on the maintenance of central memory CD4+ T populations. We characterized the function and phenotype of memory CD4+ T cells specific for mumps and influenza A or B (A/B) viruses in HIV-infected individuals. We demonstrated evidence of impaired maintenance of virus-induced or vaccine-generated central memory CD4+ T cells in HIV-infected individuals that was not restored by HAART.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Study subjects and samples

HIV-positive volunteers (n = 31) were recruited from the Study of the Consequences of the Protease Inhibitor Era (SCOPE) cohort at San Francisco General Hospital (San Francisco, CA) (22). SCOPE is an ongoing cohort of 500 HIV-1 chronically infected adults. Subjects are evaluated every 4 mo. Prestudy treatment history and treatment responses (plasma HIV RNA, CD4+ T cell count) were obtained via standardized patient interviews and medical chart review. A summary of the patient clinical data is shown in Table I. HIV RNA in the plasma (viral load) was quantified by the branched chain-DNA amplification test (Chiron, Emeryville, CA), and the lower limit of detection was 75 copies/ml. The study protocol was approved by the University of California Committee on Human Research, and all participants provided informed written consent. HIV-positive volunteers were divided into two groups: 1) 10 long-term nonprogressors (LTNP) having stable CD4+ T cell counts for >10 years and no history of any antiretroviral treatment; 2) 21 HIV-positive volunteers currently receiving HAART who had achieved either complete (HIV RNA <75 copies/ml) or partial virologic response. Ten age-matched, HIV-seronegative control volunteers were also included in the study. None of the study participants had received a mumps vaccine booster for at least 10 years, and all had Abs against mumps, influenza A, and influenza B in the plasma, as determined by the standard diagnostic test, enzyme immunoassay (California Department of Health Services, Richmond, CA) (23, 24). PBMC were separated and cryopreserved in liquid nitrogen until assay time.


View this table:
[in this window]
[in a new window]
  		Table I. Characteristics of HIV-positive volunteersa

 
Antigens

Mumps virus Ag was prepared from the Enders strain (Microbix Biosystems, Toronto, Canada). Influenza A/B virus vaccine (Fluzone; Aventis Pasteur, Swiftwater, PA) was produced for the 2002–2003 influenza season, and was formulated to contain the prototype strains of influenza A and B viruses. The vaccine was dialyzed before use to remove all traces of the preservative thimerosal.

Proliferation of memory CD4+ T cells

PBMC (2 x 106) were labeled with 4 µm CFSE (Molecular Probes, Eugene, OR) in PBS, then quenched with 100% FCS (Sigma-Aldrich, St. Louis, MO). Cells were resuspended in RPMI 1640 (Sigma-Aldrich) with 10% FCS after washing with PBS. Cells were cultured in the presence of Ag (10 µg/ml) for 5 days at 37°C in 5% CO2 and analyzed for the expression of surface markers. Media alone and PHA (10 µg/ml; Sigma-Aldrich) were used as negative and positive controls. The following Abs were used in different combinations: CD45RA PE, CD4 PerCP Cy5.5, CCR7 PE CY7, CD8 APC CY7, CD28 APC, and CD45RO APC (BD Pharmingen, San Diego, CA). Forty thousand lymphocytes per sample were acquired using an LSR II (BD Biosciences, Mountain View, CA), and analysis was performed by FLOWJO software (TreeStar, San Carlos, CA). Significant CD4+ T cell proliferation, as measured by the extent of CFSE dilution, was defined as ≥1% after subtraction of background activity. All study participants demonstrated significant proliferation following PHA stimulation. Proliferation of CD4+ T cells without Ag stimulation (negative controls) was <0.5%.

Flow-based intracellular cytokine staining

PBMC (0.5 x 106) were incubated for 2 h with Ag (10 µg/ml) at 37°C in 5% CO2 in the presence of costimulatory anti-CD49d (1 µg/ml; BD Biosciences), then brefeldin A was added for 4–6 h. Cells were washed with PBS containing 0.1% FCS (wash buffer), and fixed by resuspending the cells in lysing solution (BD Biosciences) for 10 min at room temperature. Cells were washed once with wash buffer, then permeabilized by resuspension in 0.5 ml of permeabilizing solution 2 (BD Biosciences), and incubated for 10 min at room temperature. Cells were subsequently washed with wash buffer and stained with anti-IL-2 PE, anti-CD3 PerCP Cy5.5, and CD4 APC CY7 (BD Pharmingen). Forty thousand lymphocytes per sample were acquired using an LSR II (BD Biosciences), and analysis was performed by FLOWJO software (TreeStar). Percentage of cytokine-producing CD3+/CD4+ T cells without Ag stimulation was <0.05% (negative control). Results were expressed as: net percentage of IL-2-positive CD4+ T cells (net percentage = percentage of Ag-specific – percentage of negative control).

Statistical analysis

Statistical analysis and comparisons were performed with PRISM software version 2.0 (GraphPad, San Diego, CA). Analysis was determined by Mann-Whitney U test and linear regression test. Statistical significance was defined as p < 0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Characteristics of study participants

The clinical characteristics of all HIV-positive volunteers are shown in Table I. There was no significant difference in age between the HIV-positive LTNP (aged 32–55; median = 46.5), or those receiving HAART (aged 33–66; median = 50) volunteers, and the HIV-seronegative (aged 26–61; median = 45.5) volunteers (p = 0.9 and p = 0.4, respectively). All HIV-positive and -seronegative study participants had Abs against mumps, influenza A, and influenza B virus Ags (as determined by enzyme immunoassay). HAART resulted in a significant increase in the mean CD4+ T cell count (nadir = 100; current = 382; p < 0.0001) with nine volunteers having a restored CD4+ T cell count >350 cells/mm3 (ID 2015, 2074, 2001, 2009, 2013, 3085, 3135, 3167, 3158), while seven volunteers achieved a complete virologic response (HIV RNA <75 copies/ml; ID 1092, 2015, 2070, 2074, 2001, 2009, 2013).

Phenotypic analysis of central memory CD4+ T cell subset

We first examined the phenotypes and proliferative ability of CD4+ T cells following stimulation with mumps or influenza A/B virus Ags. Representative plots of the phenotype of the proliferating mumps- and influenza A/B-specific CD4+ T cells are shown in Fig. 1, A and B, respectively. Most of the proliferating mumps-specific CD4+ T cells expressed the CD28+/CCR7+/CD45RA– phenotype in both HIV-negative (n = 10) and HIV-positive volunteers (n = 8; Fig. 1C). The proliferating influenza A/B-specific CD4+ T cells in both HIV-seronegative (n = 10) and HIV-positive (n = 9) volunteers also expressed similar phenotype (Fig. 1D). All proliferating mumps- and influenza A/B-specific CD4+ T cells expressed the memory marker CD45RO (data not shown). This is consistent with the phenotypic criteria defining CD28+/CCR7+/CD45RA–/CD45RO+ as central memory CD4+ T cells (2, 3). In addition, proliferation was associated with IL-2 production by the CD4+ T cells in both HIV-seronegative and HIV-positive volunteers in response to mumps and influenza A/B virus Ags (Fig. 2), and differences between the two groups were not statistically significant (p = 0.96 and p = 0.24 for mumps and influenza A/B, respectively).



View larger version (42K):
[in this window]
[in a new window]
  		FIGURE 1. Phenotypic analysis of mumps- and influenza-specific central memory CD4+ T cells. Representative plots of the phenotype of the proliferating mumps (A)- and influenza A/B (B)-specific CD4+ T cells. CFSE-labeled PBMC were stimulated with either mumps or influenza A/B virus Ag for 5 days, then stained for various memory surface markers and assessed for proliferation by flow cytometry. Samples were first gated on the CD4+ lymphocyte population, and percentage of proliferating CD4+ T cells, as measured by the extent of CFSE dilution, was determined. The extent of CD28, CCR7, and CD45RA expression by the proliferating CD4+ T cells was examined. *, Percentage values represent the fraction of proliferating mumps (C)- and influenza A/B (D)-specific CD4+ T cells that express CD28, CCR7, or CD45RA over the total number of proliferating CD4+ T cells (equivalent to 100%). Bars represent median values. Differences between HIV-positive and HIV-seronegative volunteers in C and D were not statistically significant (p > 0.05).

 


View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 2. Frequencies of mumps- and influenza A/B virus-specific IL-2-positive CD4+ T cells. PBMC were stimulated with mumps or influenza A/B virus Ag, then stained with anti-IL-2 PE, anti-CD3 PerCP Cy5.5, and anti-CD4 APC CY7, and analyzed by flow cytometry. Samples were first gated on the CD3+/CD4+ lymphocyte population, then the percentage of IL-2-positive cells was determined. A, Representative plots of the percentage of the mumps- and influenza A/B-specific CD4+ T cells that produce IL-2. B, Results were expressed as net percentage of mumps- or influenza A/B-specific IL-2-positive CD4+ T cells. Bars represent median values. Data are from individuals with significant mumps- or influenza A/B-specific proliferation only. Differences between HIV-positive and HIV-seronegative volunteers in B were not statistically significant (p > 0.05).

 
Effect of HIV infection on maintenance of mumps- and influenza-specific central memory CD4+ T cell responses

We next examined the effect of chronic HIV infection on the maintenance of memory CD4+ T cells specific for mumps and influenza A/B virus Ags. All HIV-seronegative volunteers (n = 10) demonstrated significant proliferative responses to both mumps (median = 2.05%; Fig. 3A) and influenza A/B (median = 4.75%; Fig. 3B) virus Ags. Similarly, 8 of 10 and 9 of 10 HIV-positive LTNP volunteers displayed significant proliferative responses to mumps (median = 1.6%) and influenza A/B (median = 7.75%) virus Ags, respectively. The responses in HIV-seronegative and HIV-positive LTNP volunteers had similar magnitude that was not statistically significant (p = 0.2 and p = 0.9, for mumps and influenza A/B, respectively). In contrast, none of the HIV-positive volunteers receiving HAART (n = 21) generated proliferative responses to mumps or influenza A/B virus Ags (Fig. 3, respectively). These results were observed in volunteers who demonstrated restored CD4+ T cell count, as well as in volunteers who achieved a complete virologic response. Differences in responses between HIV-positive volunteers receiving HAART compared with HIV LTNP or HIV-seronegative volunteers were significant for mumps (p < 0.0001 and p < 0.0001, respectively) and influenza A/B (p < 0.0001 and p < 0.0001, respectively) virus Ags. This lack of Ag-specific proliferation suggests that chronic HIV infection is associated with impaired maintenance of central memory CD4+ T cell responses to mumps, influenza A, and influenza B viruses.



View larger version (13K):
[in this window]
[in a new window]
  		FIGURE 3. Magnitude of mumps- and influenza A/B-specific central memory CD4+ T cell proliferation in HIV-positive individuals. CFSE-labeled PBMC were stimulated with mumps (A) or influenza A/B virus (B) Ag for 5 days, then assessed for proliferation by flow cytometry. Results are percentage of proliferating CD4+ T cells as measured by the extent of CFSE dilution. Bars represent median values. Dashed line represents the cutoff for significant proliferation. Differences in A and B between HIV-positive volunteers receiving HAART compared with HIV-positive LTNP or HIV-seronegative volunteers were statistically significant (p < 0.0001 and p < 0.0001, respectively). No statistically significant differences were found between HIV-positive LTNP and HIV-seronegative volunteers (p > 0.05) in either A or B.

 
Effect of HAART on maintenance of central memory CD4+ T cell responses

None of the HIV-positive volunteers receiving HAART who had a restored CD4+ T cell count or had achieved a complete virologic response demonstrated significant central memory CD4+ T cell responses to either mumps (Fig. 4A) or influenza A/B (Fig. 4B) virus Ags. Surprisingly, the two HIV-positive LTNP, who had a nadir CD4+ T cell count ≤350 cells/mm3, also demonstrated no significant central memory CD4+ T cell responses to mumps (Fig. 4A), and only one of two was able to maintain significant central memory CD4+ T cell responses to influenza A/B (Fig. 4B). In contrast, all of the HIV-positive LTNP, who had a nadir CD4+ T cell count >350 cells/mm3 (n = 8), were able to maintain significant central memory CD4+ T cell responses to mumps (Fig. 4A) and influenza A/B (Fig. 4B) virus Ags.



View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 4. Relation of mumps- and influenza A/B-specific central memory CD4+ T cell proliferation to the nadir CD4+ T cell count in HIV-positive individuals. CFSE-labeled PBMC were stimulated with mumps (A) or influenza A/B virus (B) Ag for 5 days, then assessed for proliferation by flow cytometry. Results are percentage of proliferating CD4+ T cells as measured by the extent of CFSE dilution. Dashed line represents the cutoff for significant proliferation. Differences in A between 4 vs 1, 2, or 3 were statistically significant (p = 0.0003, p < 0.0001, and p = 0.04, respectively). Differences in B between 4 vs 1 or 2 were statistically significant (p = 0.0003 and p < 0.0001, respectively). Differences between 4 vs 3 in B, between 1 vs 2 or 3 and between 2 vs 3 in A and B were not statistically significant (p > 0.05).

 
Previous studies have demonstrated that HIV viremia correlated with diminished HIV-specific CD4+ T cell proliferation in chronic HIV infection (25, 26). We determined the relationship between HIV viral load and the magnitude of central memory CD4+ T cell responses and found no correlation between the viral load and responses to mumps (Fig. 5A) or influenza A/B (Fig. 5B) virus Ags.



View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 5. Relation of mumps- and influenza A/B-specific central memory CD4+ T cell proliferation to HIV RNA titer. The CD4+ T cell proliferative response to mumps (A) and influenza A/B virus (B) Ag, as measured by flow cytometry, is plotted against the HIV RNA titers (copies x 102/ml). No correlation between the two parameters was observed in A, R2 = 0.008, p = 0.62 or B, R2 = 0.03, p = 0.35.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The hallmark of immune protection is the long-term maintenance of memory T cell responses. CD4+ T cell help is required for the control of infection and for the generation of functional memory CD8+ T cells (27, 28). A strong CD4+ T cell response has been correlated with better control of HIV infection (29). However, the mechanism by which HIV affects the homeostasis and the proliferative ability of memory CD4+ T cells remains unresolved (reviewed in Ref.30).

We first characterized the central memory CD4+ T cells specific for mumps and influenza A/B virus Ags in a cohort of chronic HIV-infected volunteers. HIV-positive LTNP maintained significant proliferative responses to mumps and influenza A/B virus Ags comparable to that observed in HIV-seronegative volunteers. Detection of mumps-specific responses >10 years after natural infection or immunization suggests that central memory CD4+ T cells are long-lived in the absence of Ag re-exposure. These results also suggest that the ability to generate or maintain effective central memory CD4+ T cell responses is preserved in nonprogressive HIV disease with low-level HIV replication.

In contrast, none of the antiretroviral treated individuals had detectable proliferative responses to either mumps or influenza A/B virus Ags. This lack of responses persisted even in individuals with clear evidence of a treatment-mediated increase in CD4+ T cell count and low or undetectable viremia. These results suggest that progressive HIV disease may cause global impaired maintenance of central memory CD4+ T cell responses, and that reconstitution of pre-existing immunity remains defective despite viral suppression and normalization of CD4+ T cell count in response to HAART.

Data from several cohort studies support initiating treatment of HIV-positive individuals when CD4+ T cell count reaches 200 cells/mm3 (31, 32, 33). Introduction of HAART has significantly reduced HIV-related morbidity and mortality (11, 12, 13, 14). However, the optimal time to initiate HAART in asymptomatic HIV-positive individuals with CD4+ T cell count of <350 cells/mm3 is still debated (reviewed in Ref.34). In our study, indicators of clinical responses to HAART including restored current CD4+ T cell count or suppression of HIV replication had no impact on maintaining effective virus-induced or vaccine-generated central memory CD4+ T cell responses. In contrast, low nadir CD4+ T cell count (≤350 cells/mm3) predicted failure to preserve these responses. The ability to maintain central memory CD4+ T cell responses in our HIV-positive study participants may reflect on immunologic characteristics specific to HIV-positive LTNP. However, the two LTNP that had a low nadir CD4+ T cell count (≤350 cells/mm3) were also unable to maintain mumps-specific central memory CD4+ T cell responses. This interesting finding leads us to postulate that a low nadir CD4+ T cell count results in a permanent loss of the long-lived Ag-specific central memory CD4+ T cells. Our findings should contribute to decisions toward initiation of antiretroviral therapy and strategies of vaccination targeted to the HIV-infected population.


   Acknowledgments
 
We thank Dr. Mark Eggena for his critical review of this manuscript.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by grants from National Institutes of Health: AI-43754-05, AI052745, AI055273; California AIDS Research Center: CC99-SF, ID01-SF-049; University of California/Gladstone Institute of Virology & Immunology Center for AIDS Research: P30 MH59037, P30 AI27763; and Center for AIDS Prevention Studies: P30 MH62246. Back

2 Address correspondence and reprint requests to Dr. Mohamed Elrefaei, California Department of Health Services, 850 Marina Bay Parkway, Viral and Rickettsial Disease Lab, Richmond, CA 94804. E-mail address: melrefae{at}dhs.ca.gov Back

3 Abbreviations used in this paper: HAART, highly active antiretroviral therapy; LTNP, long-term nonprogressor. Back

Received for publication January 27, 2004. Accepted for publication May 20, 2004.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Seder, R. A., R. Ahmed. 2003. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat. Immunol. 4:835.[Medline]
  2. Sallusto, F., D. Lenig, R. Forster, M. Lipp, A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708.[Medline]
  3. Younes, S. A., B. Yassine-Diab, A. R. Dumont, M. R. Boulassel, Z. Grossman, J. P. Routy, R. P. Sekaly. 2003. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J. Exp. Med. 198:1909.[Abstract/Free Full Text]
  4. Riberdy, J. M., J. P. Christensen, K. Branum, P. C. Doherty. 2000. Diminished primary and secondary influenza virus-specific CD8+ T-cell responses in CD4-depleted Ig–/– mice. J. Virol. 74:9762.[Abstract/Free Full Text]
  5. Borrow, P., D. F. Tough, D. Eto, A. Tishon, I. S. Grewal, J. Sprent, R. A. Flavell, M. B. Oldstone. 1998. CD40 ligand-mediated interactions are involved in the generation of memory CD8+ cytotoxic T lymphocytes (CTL) but are not required for the maintenance of CTL memory following virus infection. J. Virol. 72:7440.[Abstract/Free Full Text]
  6. Von Herrath, M. G., M. Yokoyama, J. Dockter, M. B. Oldstone, J. L. Whitton. 1996. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol. 70:1072.[Abstract]
  7. Lane, H. C., J. M. Depper, W. C. Greene, G. Whalen, T. A. Waldmann, A. S. Fauci. 1985. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome: evidence for a selective defect in soluble antigen recognition. N. Engl. J. Med. 313:79.[Abstract]
  8. Lang, W., H. Perkins, R. E. Anderson, R. Royce, N. Jewell, W. Winkelstein, Jr. 1989. Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J. Acquired Immune Defic. Syndr. 2:63.
  9. Dolan, M. J., M. Clerici, S. P. Blatt, C. W. Hendrix, G. P. Melcher, R. N. Boswell, T. M. Freeman, W. Ward, R. Hensley, G. M. Shearer. 1995. In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J. Infect. Dis. 172:79.[Medline]
  10. Clerici, M., N. I. Stocks, R. A. Zajac, R. N. Boswell, D. R. Lucey, C. S. Via, G. M. Shearer. 1989. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients: independence of CD4+ cell numbers and clinical staging. J. Clin. Invest. 84:1892.
  11. Palella, F. J., Jr, K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, S. D. Holmberg. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N. Engl. J. Med. 338:853.[Abstract/Free Full Text]
  12. Valdez, H., T. K. Chowdhry, R. Asaad, I. J. Woolley, T. Davis, R. Davidson, N. Beinker, B. M. Gripshover, R. A. Salata, G. McComsey, et al 2001. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995–1999. Clin. Infect. Dis. 32:1487.[Medline]
  13. Mocroft, A., C. Katlama, A. M. Johnson, C. Pradier, F. Antunes, F. Mulcahy, A. Chiesi, A. N. Phillips, O. Kirk, J. D. Lundgren. 2000. AIDS across Europe, 1994–98: the EuroSIDA study. Lancet 356:291.[Medline]
  14. Mocroft, A., S. Vella, T. L. Benfield, A. Chiesi, V. Miller, P. Gargalianos, A. d’Arminio Monforte, I. Yust, J. N. Bruun, A. N. Phillips, J. D. Lundgren. 1998. Changing patterns of mortality across Europe in patients infected with HIV-1: EuroSIDA Study Group. Lancet 352:1725.[Medline]
  15. Valdez, H.. 2002. Immune restoration after treatment of HIV-1 infection with highly active antiretroviral therapy (HAART). AIDS Rev. 4:157.[Medline]
  16. Kroon, F. P., G. F. Rimmelzwaan, M. T. Roos, A. D. Osterhaus, D. Hamann, F. Miedema, J. T. van Dissel. 1998. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 12:F217.[Medline]
  17. Valdez, H., K. Y. Smith, A. Landay, E. Connick, D. R. Kuritzkes, H. Kessler, L. Fox, J. Spritzler, J. Roe, M. B. Lederman, et al 2000. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen: ACTG 375 team: AIDS Clinical Trials Group. AIDS 14:11.[Medline]
  18. Autran, B., G. Carcelain, T. S. Li, C. Blanc, D. Mathez, R. Tubiana, C. Katlama, P. Debre, J. Leibowitch. 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112.[Abstract/Free Full Text]
  19. Lange, C. G., H. Valdez, K. Medvik, R. Asaad, M. M. Lederman. 2002. CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin. Immunol. 102:154.[Medline]
  20. Pakker, N. G., E. D. Kroon, M. T. Roos, S. A. Otto, D. Hall, F. W. Wit, D. Hamann, M. E. van der Ende, F. A. Claessen, R. H. Kauffmann, et al 1999. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy: INCAS Study Group. AIDS 13:203.[Medline]
  21. Lederman, H. M., P. L. Williams, J. W. Wu, T. G. Evans, S. E. Cohn, J. A. McCutchan, S. L. Koletar, R. Hafner, E. Connick, F. T. Valentine, et al 2003. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J. Infect. Dis. 188:1794.[Medline]
  22. Hunt, P. W., J. N. Martin, E. Sinclair, B. Bredt, E. Hagos, H. Lampiris, S. G. Deeks. 2003. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J. Infect. Dis. 187:1534.[Medline]
  23. Cremer, N. E., C. K. Cossen, G. Shell, J. Diggs, D. Gallo, N. J. Schmidt. 1985. Enzyme immunoassay versus plaque neutralization and other methods for determination of immune status to measles and varicella-zoster viruses and versus complement fixation for serodiagnosis of infections with those viruses. J. Clin. Microbiol. 21:869.[Abstract/Free Full Text]
  24. Julkunen, I., M. Kleemola, T. Hovi. 1984. Serological diagnosis of influenza A and B infections by enzyme immunoassay: comparison with the complement fixation test. J. Virol. Methods 9:7.[Medline]
  25. Scott, Z. A., C. M. Beaumier, M. Sharkey, M. Stevenson, K. Luzuriaga. 2003. HIV-1 replication increases HIV-specific CD4+ T cell frequencies but limits proliferative capacity in chronically infected children. J. Immunol. 170:5786.[Abstract/Free Full Text]
  26. Iyasere, C., J. C. Tilton, A. J. Johnson, S. Younes, B. Yassine-Diab, R. P. Sekaly, W. W. Kwok, S. A. Migueles, A. C. Laborico, W. L. Shupert, et al 2003. Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J. Virol. 77:10900.[Abstract/Free Full Text]
  27. Sun, J. C., M. J. Bevan. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300:339.[Abstract/Free Full Text]
  28. Shedlock, D. J., H. Shen. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337.[Abstract/Free Full Text]
  29. Rosenberg, E. S., J. M. Billingsley, A. M. Caliendo, S. L. Boswell, P. E. Sax, S. A. Kalams, B. D. Walker. 1997. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278:1447.[Abstract/Free Full Text]
  30. Douek, D. C., L. J. Picker, R. A. Koup. 2003. T cell dynamics in HIV-1 infection. Annu. Rev. Immunol. 21:265.[Medline]
  31. Egger, M., M. May, G. Chene, A. N. Phillips, B. Ledergerber, F. Dabis, D. Costagliola, A. D’Arminio Monforte, F. de Wolf, P. Reiss, et al 2002. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360:119.[Medline]
  32. Palella, F. J., Jr, M. Deloria-Knoll, J. S. Chmiel, A. C. Moorman, K. C. Wood, A. E. Greenberg, S. D. Holmberg. 2003. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann. Intern. Med. 138:620.[Abstract/Free Full Text]
  33. Hogg, R. S., B. Yip, K. J. Chan, E. Wood, K. J. Craib, M. V. O’Shaughnessy, J. S. Montaner. 2001. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. J. Am. Med. Assoc. 286:2568.[Abstract/Free Full Text]
  34. Thorner, A., E. Rosenberg. 2003. Early versus delayed antiretroviral therapy in patients with HIV infection: a review of the current guidelines from an immunological perspective. Drugs 63:1325.[Medline]



This article has been cited by other articles:


Home page
 Int J STD AIDSHome page
H N. Kim, R. D Harrington, S. E V. Rompaey, and M. M Kitahata
Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons
Int J STD AIDS, September 1, 2008; 19(9): 600 - 604.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S.-A. Younes, L. Trautmann, B. Yassine-Diab, L. H. Kalfayan, A.-E. Kernaleguen, T. O. Cameron, R. Boulassel, L. J. Stern, J.-P. Routy, Z. Grossman, et al.
The Duration of Exposure to HIV Modulates the Breadth and the Magnitude of HIV-Specific Memory CD4+ T Cells
J. Immunol., January 15, 2007; 178(2): 788 - 797.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. M. Cohen, S. Pouvelle-Moratille, X.-F. Wang, S. Farci, G. Munier, D. Charron, A. Menez, M. Busson, and B. Maillere
Scanning the HIV Genome for CD4+ T Cell Epitopes Restricted to HLA-DP4, the Most Prevalent HLA Class II Molecule
J. Immunol., May 1, 2006; 176(9): 5401 - 5408.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Elrefaei, B. Barugahare, F. Ssali, P. Mugyenyi, and H. Cao
HIV-Specific IL-10-Positive CD8+ T Cells Are Increased in Advanced Disease and Are Associated with Decreased HIV-Specific Cytolysis
J. Immunol., January 15, 2006; 176(2): 1274 - 1280.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Piriou, C. A. Jansen, K. v. Dort, I. De Cuyper, N. M. Nanlohy, J. M. A. Lange, M. H. J. van Oers, F. Miedema, and D. van Baarle
Reconstitution of EBV Latent but Not Lytic Antigen-Specific CD4+ and CD8+ T Cells after HIV Treatment with Highly Active Antiretroviral Therapy
J. Immunol., August 1, 2005; 175(3): 2010 - 2017.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elrefaei, M.
Right arrow Articles by Cao, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elrefaei, M.
Right arrow Articles by Cao, H.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*AIDS Medicines

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS